GlobeNewswire by notified

AKVA group ASA: Q1 2024 financial reporting

Share

Acceptable activity level in Sea Based and improved profitability.

AKVA group delivered revenue for Q1 2024 of MNOK 784 (874), a decrease of 10% compared to Q1 2023.

EBITDA increased from MNOK 59 in Q1 2023 to MNOK 67 in Q1 2024.

Total order intake of MNOK 917 (1,170) in Q1 2024 supported by strong order intake of MNOK 800 in Sea Based. Order backlog of BNOK 2,6 at the end of March 2024.

Award of three new barges for the Nordic market with a total contract value of approx. MNOK 160.

The activity level in Sea Based was acceptable in the first quarter of 2024 with a strong order intake of MNOK 800. The high order intake was driven by the award of three new barges for the Nordic market. The market for Land Based is still slow and AKVA does not expect to sign any new significant contracts during the first half of 2024. The outlook for the post smolt market in Norway is still challenging due to the resource tax but is expected to normalize during the second half of 2024.

Profitability improved compared to last year but is still below expectations. The profit margin in the Land Based business is influenced by the low activity level and to some extent closing of old contracts. The profitability in Sea Based is acceptable supported by a healthy product mix.

Sea Based Technology (SBT)
SBT revenue for Q1 2024 ended at MNOK 646 (655). EBITDA and EBIT for the segment in Q1 ended at MNOK 64 (55) and MNOK 29 (19), respectively. The related EBITDA and EBIT margins were 10.0% (8.5%) and 4.5% (2.9%), respectively.

Order intake in Q1 2024 was MNOK 800 compared to MNOK 613 in Q1 2023. Order backlog ended at MNOK 946 compared to MNOK 861 last year.

The Nordic region experienced a increase in revenue from MNOK 425 in Q1 2023 to MNOK 428 in Q1 2024.

In the Americas region, the revenue was MNOK 150, which is an increase from 121 MNOK in the first quarter last year.

Europe and Middle East (EME) had a revenue of MNOK 68 in Q1 2024, compared to the revenue of MNOK 109 in the first quarter last year.

Land Based Technology (LBT)
Revenues for the first quarter were MNOK 101 (192). EBITDA and EBIT ended at MNOK -3 (-2) and MNOK -6 (-5), respectively. The related EBITDA and EBIT margins were -3.2% (-1.3%) and -5.8% (-2.4%).

Order intake in Q1 2024 was MNOK 72 compared to MNOK 527 in Q1 2023. Order backlog ended at MNOK 1,495, compared to MNOK 1,018 last year.

Digital (DI)
The revenue in the segment was MNOK 37 (27) in Q1 2024. EBITDA and EBIT ended at MNOK 6 (6) and MNOK -3 (-4), respectively. The related EBITDA and EBIT margins were 17,4% (21,8%) and -7,6% (-13.3%).

Order intake in Q1 2024 was MNOK 45 compared to MNOK 30 in Q1 2023. Order backlog ended at MNOK 158, compared to MNOK 106 last year.

Balance sheet
Working capital as a percentage of 12 months rolling revenue is 11.3% (8.2%). Cash and unused credit facilities amounted to MNOK 283 (629) at the end of Q1. Total assets and total equity amounted to MNOK 3,767 and MNOK 1,163 respectively, resulting in an equity ratio of 30.9% (32.8%) at the end of Q1 2024.

Dividend
The Company’s main objective is to maximize the return on the investment made by its shareholders through both increased share prices and dividend payments. The company has decided not to pay any dividend in the first half of 2024, and will make a new evaluation for the second half year ahead of Q2 reporting in August.

Order Backlog
The order backlog at the end of Q1 was MNOK 2,599 (1,984). MNOK 1,495 or 58% of total order backlog at the end of Q1 relates to Land Based Technology (LBT).

Outlook
Salmon prices are expected to remain strong driven by reduced supply.

AKVA expects to see a normalization of the post smolt market in Norway during the second half of 2024.

As previous announced, AKVA is aiming for a revenue of minimum BNOK 3,6 and EBIT of 4-5% in 2024.

About AKVA group
AKVA group is a technology and service partner to the aquaculture industry worldwide. The company has 1 425 employees, offices in 11 countries and had a total turnover of NOK 3.4 billion in 2023. We are a public listed company operating in one of the world’s fastest growing industries and supply everything from single components to complete installations, both for sea farming and land based aquaculture. AKVA group is recognized as a pioneer and technology leader through more than 40 years.

Dated: 3 May 2024
AKVA group ASA

Web: www.akvagroup.com

CONTACTS:

Knut Nesse Chief Executive Officer
Phone:+47 51 77 85 00
Mobile:+47 91 37 62 20
E-mail:knesse@akvagroup.com


Ronny MeinkøhnChief Financial Officer
Phone:+47 51 77 85 00
Mobile:+47 98 20 67 76
E-mail:rmeinkohn@akvagroup.com


This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Subsea7 awarded a contract for the Belinda field in the UK North Sea25.5.2024 14:01:09 CEST | Press release

Luxembourg – 25 May 2024 - Subsea7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a sizeable1 contract by Serica Energy, for the Belinda field development south-east of the Triton FPSO. The Belinda field is operated by Serica Energy and located approximately 190 kilometres east of Aberdeen in the UK Central North Sea, with a water depth of 95 metres. The contract scope includes project management, engineering, procurement, construction and installation (EPCI) of a 5-kilometre 8” production pipeline with a 3” piggy-backed gas lift line and an electro-hydraulic controls (EHC) umbilical. Subsea7’s scope also includes associated subsea structures and tie-ins to the Triton Floating Production Storage & Offloading (FPSO) vessel operated by Dana Petroleum, via an existing production manifold near the Triton riser base and for controls at the Evelyn valve skid. Project management and engineering work will commence immediately in Aberdeen. The offshore activities are scheduled

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio25.5.2024 12:15:00 CEST | Press release

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor,demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1 Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN2-5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population1 IgAN is a heterogeneous, progressive, rare kidney disease with a need for effective, targeted therapies6,7; up to 30% of patients with persistent proteinuria (≥1 g/day) progress to kidney failure within 10 years8 Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression Basel, May 25, 2024 – Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atr

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo25.5.2024 12:00:00 CEST | Press release

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2,3Fabhalta showed a favorable safety profile with no new safety signals1C3G, an ultra-rare kidney disease caused by alternative complement pathway overactivation, progresses to kidney failure in ∼50% of patients within 10 years4-7; currently there are no treatments approved for C3G7-9 Fabhalta, an oral Factor B inhibitor of the alternative complement pathway, selectively targets the underlying cause of C3G1; late-stage development program ongoing across several other rare diseases10-13 Basel, May 25, 2024 – Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to support

Metasphere Labs Announces Development of Innovative Carbon Credit Protocol for Grid-Scale Batteries24.5.2024 22:05:00 CEST | Press release

VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is excited to announce an innovative initiative aimed at accelerating the decarbonization of the electricity grid through the development of a pioneering carbon credit protocol for grid-scale batteries. Innovative Carbon Credit Protocol The Company is committed to leveraging advanced technology to address critical environmental challenges. The new carbon credit protocol will enable grid-scale batteries to monetize their environmental attributes by generating carbon credits for the carbon reductions achieved through optimized battery operations. This protocol is designed to incentivize the deployment and operation of grid-scale batteries, ensuring they play a pivotal role in the transition to a clean energy future. Submission to Pure Sky Carbon Credit Registry The Company intends to submit this pr

Nokia Corporation: Repurchase of own shares on 24.05.202424.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 24 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 24.05.2024 Espoo, Finland – On 24 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,1533.55CEUX--BATE--AQEU--TQEX--Total362,1533.55 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

HiddenA line styled icon from Orion Icon Library.Eye